https://www.thebodypro.com/category/rilpivirine-edurant/tag/news

The Latest

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies Img

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

Anton Pozniak at the 90-90-90 Targets Workshop

How Will Long-Acting HIV Antiretrovirals Work in the Real World?

Once viable long-acting HIV prevention and treatment options have reached the market, what will be their true impact? Leading HIV clinician-researcher Anton Pozniak, M.D., shares his expertise.

Two-Drug HIV Treatment Regimens Effective in Latest Studies Img

Two-Drug HIV Treatment Regimens Effective in Latest Studies

"This is really the first step in demonstrating that two-drug regimens can be as effective as three-drug regimens," says Kimberly Smith, M.D., M.P.H.

Single Injected Dose of Long-Acting Rilpivirine Inhibits HIV in Rectal Tissue Img

Single Injected Dose of Long-Acting Rilpivirine Inhibits HIV in Rectal Tissue

A single intramuscular dose of long-acting rilpivirine (Edurant) significantly lowered HIV in rectal tissue but not in vaginal or cervical tissue, according to a recent study.

Rilpivirine as HIV PrEP Remains in Body 18 Months After Single Long-Acting Shot Img

Rilpivirine as HIV PrEP Remains in Body 18 Months After Single Long-Acting Shot

Rilpivirine (Edurant) remained detectable in plasma and female genital tract fluids for 18 months or more after a single injection of a long-acting non-nucleoside for HIV pre-exposure prophylaxis (PrEP).

Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results Img

Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results

Rilpivirine (Edurant) plus ritonavir-boosted darunavir (Prezista) as HIV maintenance therapy compared similarly to a three-drug regimen of a boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors, according to a study presente...

Pharmacokinetics of Antiretrovirals in Pregnancy: Rilpivirine, Etravirine and Raltegravir Img

Pharmacokinetics of Antiretrovirals in Pregnancy: Rilpivirine, Etravirine and Raltegravir

Three posters at CROI 2015 described pharmacokinetics of antiretrovirals in pregnancy for rilpivirine, etravirine and raltegravir. None of the studies suggested that dose adjustment is required.

Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep Img

Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep

Switching from efavirenz/tenofovir/emtricitabine (Atripla) to rilpivirine/tenofovir/emtricitabine (Complera) significantly relieved central nervous system (CNS) toxicity and improved sleep in people with those problems while taking Atripla.

Promo Image

Single-Tablet Regimen Containing Rilpivirine and Dolutegravir Being Developed for HIV

A single-tablet formulation containing two drugs is currently being developed as maintenance therapy for people living with HIV. The new medication, being developed by Janssen R&D Ireland Ltd and ViiV Healthcare, will combine the NNRTI (non-nucleosid...

Promo Image

Agreement to Develop Long-Acting Rilpivirine as PrEP

On 25 September 2013, Janssen announced that it had signed a license agreement with international nonprofit health organisation PATH for early stage research to develop a long acting depot formulation of rilpivirine as a potential pre-exposure prophy...